© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Success as a CEO  in Drug Development
Posted 26th June 2017

Success as a CEO in Drug Development

Under the Business Elite Awards 2017, the exclusive CEO of the Year - Italy award when in the direction of Francesco Sinigaglia, CEO and cofounder of Anabasis. We spoke to the man himself to find out more about his key role in the company, before he sold it to Dompé in 2011.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Success as a CEO in Drug Development
Image

Under the Business Elite Awards 2017, the exclusive CEO of the Year – Italy award when in the direction of Francesco Sinigaglia, CEO and cofounder of Anabasis. We spoke to the man himself to find out more about his key role in the company, before he sold it to Dompé in 2011.

Francesco Sinigaglia is the CEO and co-founder of Anabasis, an Italian biopharmaceutical company developing Nerve Growth Factor (NGF) for severe eye diseases. In 2011, he sold Anabasis to Dompé for approximately 10 million upfront and 160 million in regulatory and commercial milestones. Francesco’s industry expertise lies in the life science, biotechnology and pharmaceutical sectors.

He starts the interview by detailing his role following the acquisition and his undoubted experience as a seasoned professional in the industry, plus his reflections on his greatest professional achievement to date.

“After the acquisition, I remained on board as COO to complete the development of the NGF. It was a great success, indeed NGF is now being approved in the EU by European Medicines Agency (EMA).

“Going back a bit, I spent more than 35 years in the biotech and pharmaceutical industry. This included 20 years at Roche, with the first 10 of these at the company’s headquarters in Basel and then as a research director in Italy. In 2002, I founded my first biotech company, Bioxell, that I took public on the Swiss Stock Exchange in 2006 and sold it to Cosmo Pharmaceutical three years later. In 2009, I founded the company Anabasis.

“My biggest achievement is the success of Anabasis, both in terms of scientific and clinical development and for the ability to create value. We financed the development programmes by ourselves and through the collaboration agreement with Dompé, thus avoiding the financial support of venture capital and consequently value dilution.”

Francesco then offers his thoughts on what makes him stand out from other CEO’s and the advice he would you give to anyone wishing to pursue the same career route.

“Drug development is a difficult and risky business. Indeed, only a very few drugs are approved each year and these are mostly from large multinational organisations. To have been able, with rather limited resources, to complete the preclinical, clinical and regulatory development and obtain approval by the regulatory authorities is indeed for me a very major achievement.

“For anybody wishing to take the same career route as me, I would underline that, if you believe that you have a good business idea, just go for it don’t be afraid to fail. It is very true to say that failure is a very important component of the learning process.”

Finally, Francesco draws our attention to another accolade he has won over the past 12 months, including the Best Biopharmaceutical Company – Italy and Excellence Award for Industrial Research 2017, as well as the Business Elite Awards 2017 CEO of the Year – Italy award that this feature interview celebrates.

Categories: Leadership


You Might Also Like
Read Full PostRead - Eye Icon
Hard Landings and High Stakes: Legal Considerations After a Traumatic Aircraft Touchdown
Legal
26/01/2026Hard Landings and High Stakes: Legal Considerations After a Traumatic Aircraft Touchdown

Commercial aviation is designed around precision, safety, and rigorous operational standards. However, when an aircraft experiences a hard or unstable landing, the consequences can extend far beyond temporary discomfort. These incidents can result in serious p

Read Full PostRead - Eye Icon
5 Reasons Every Startup Must Calculate Their Market Size
News
27/06/20225 Reasons Every Startup Must Calculate Their Market Size

Building a successful startup goes beyond developing a product or service—you must be sure you are diving into a profitable market, and your product can cater to consumers' needs.

Read Full PostRead - Eye Icon
Giving A Personal Touch to Clinical Trials
Innovation
01/03/2018Giving A Personal Touch to Clinical Trials

GlobalCare Clinical Trials brings over 100 years of experience in the clinical trials and home healthcare industries supporting over 400 studies in over 50 countries by effectively delivering high quality and convenient clinical trial services in the home or a

Read Full PostRead - Eye Icon
Can Automation Help to Eradicate Human Error in the Workplace?
Innovation
27/09/2022Can Automation Help to Eradicate Human Error in the Workplace?

Each day, businesses across the country handle countless transactions and obtain vast amounts of data. Unfortunately, while processing and utilizing this data, the opportunity for human error is high. These mistakes can be costly.

Read Full PostRead - Eye Icon
A Notary for Your Diary – The Seal of Approval That Every Business Needs
Legal
22/01/2015A Notary for Your Diary – The Seal of Approval That Every Business Needs

With only 800 in the country, finding and accessing a Notary Public for England and Wales can take up valuable time and resources.

Read Full PostRead - Eye Icon
3 Best Business Mapping Software for Territory Management
Technology
20/04/20263 Best Business Mapping Software for Territory Management

Poorly drawn sales territories cost real money. Harvard Business Review published findings showing that optimised territory design can increase sales by up to 7%. Alexander Group reported productivity gains between 10% and 20% in organisations that replaced ma

Read Full PostRead - Eye Icon
7 Best SOC 2 Compliance Software in 2024
News
26/07/20247 Best SOC 2 Compliance Software in 2024

7 Best SOC 2 Compliance Software in 2024 With cybersecurity threats on the rise and becoming more sophisticated by the day, SOC 2 compliance is becoming a real non-negotiable for businesses to assure customers and stakeholders that they take their security and

Read Full PostRead - Eye Icon
CEO of the Month – UK
Leadership
03/06/2016CEO of the Month – UK

With offices in London, UK and Chicago, USA, Adgistics is a marketing technology solution provider that helps to grow the value of brand assets for global businesses

Read Full PostRead - Eye Icon
Technology M&A – Shifting Paradigms
Innovation
15/07/2016Technology M&A – Shifting Paradigms

M&A in the technology, media and entertainment (TME) space has boomed over the last 24 months and while Brexit may dent confidence and activity, arguably this sector is better placed than most to remain buoyant.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow